Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Gestational Diabetes
Interventions
DRUG

Exenatide

10 microgram injected sub-cutaneously once

GENETIC

Buccal/blood Sample Collection

Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing

Trial Locations (2)

20007

Georgetown University Medical Center, Washington D.C.

20010

Washington Hospital Center, Washington D.C.

Sponsors
All Listed Sponsors
collaborator

Medstar Health Research Institute

OTHER

lead

Georgetown University

OTHER